KisoJi Biotechnology

What KisoJi Biotechnology does

KisoJi Biotechnology is a Canadian clinical-stage biopharmaceutical company developing antibody therapeutics, headquartered in Montreal with a research laboratory at the Princess Margaret Cancer Research Tower in Toronto. The company has built an integrated antibody discovery platform composed of three proprietary technology components: KisoMouse, a multi-species transgenic mouse platform that generates highly diverse single domain antibodies; KisoSeek, an AI-enabled paratope mapping technology that uses next-generation sequencing and AI tools to visualize the complete immune response against a given target and guide antibody selection; and KisoBody, a modular multi-specific antibody format designed to target multiple antigens or epitopes simultaneously, with reported tri-specific antibody titers exceeding 6 g/L in commercial production cell lines. From this platform, KisoJi has built a preclinical-to-early-clinical pipeline led by KJ-103, a first-in-class naked anti-TROP2 antibody for TROP2-expressing solid tumors currently in IND-enabling studies, alongside KJ-101 (tri-specific PD-1/CD47/D2 antibody for solid tumors in IND-enabling studies) and KJ-102 (tri-specific PD-1/CD47/CD36 antibody for acute myeloid leukemia in research stage).

The company's business model is a pre-commercial licensing and partnership model rather than direct product sales. KisoJi has no commercialized products and generates no product revenue today; instead, it pursues clinical development partnerships with major research organizations (notably Cancer Research UK, which is sponsoring a Phase 1/2a trial of KJ-103 in approximately 100 patients) and targets eventual out-licensing or acquisition transactions with larger pharmaceutical companies. The company is supported by a syndicate of institutional and strategic investors, having raised $41 million in equity financing in December 2024 led by Investissement Quebec and Lumira Ventures, with participation by Fonds de solidarité FTQ, adMare BioInnovations, and Remiges Ventures. End therapeutic markets include oncology (TROP2-expressing solid tumors across colorectal, head and neck, ovarian, breast, bladder, and lung cancers, plus acute myeloid leukemia), with planned pipeline expansion into cardiometabolic disease, immunology, and inflammation.

Name

KisoJi Biotechnology

Legal name

KisoJi Biotechnology Inc.

Website

https://www.kisojibiotech.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

KisoJi Biotechnology is a Canadian clinical-stage biopharmaceutical company developing antibody therapeutics for oncology and other diseases. It uses a proprietary platform combining transgenic single-domain antibody mice, AI-enabled paratope mapping, and a modular multi-specific antibody format, and it generates value through licensing and partnerships.

Ownership category

akta.pro rank

Product category

Therapeutic Antibody Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Therapeutic antibody discovery
• Single domain antibodies
• Multi-specific antibody engineering
• Transgenic antibody platform
• Oncology biopharmaceuticals

Headquarters

HQ city

Laval-ouest

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutic antibody development and licensing: As a pre-clinical/early clinical stage biotechnology company, KisoJi generates value through developing proprietary antibody therapeutics and pursuing licensing deals or acquisitions with larger pharmaceutical companies. The company is advancing its own pipeline of antibody candidates (KJ-101, KJ-102, KJ-103) while leveraging its discovery platform for partnership opportunities.
2. Platform technology partnerships: KisoJi may generate revenue through partnerships with pharmaceutical companies that seek to utilize the company's antibody discovery platform for their own therapeutic programs, including the AI-enabled paratope fingerprinting technology and multi-specific antibody scaffold.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

KisoJi Biotechnology discovers and develops differentiated antibody therapeutics using an integrated platform comprising multi-species transgenic single domain antibody mice (KisoMouse), AI-enabled paratope fingerprinting (KisoSeek), and a modular multi-specific antibody format (KisoBody). Its product pipeline includes lead asset KJ-103, a first-in-class naked anti-TROP2 antibody in IND-enabling studies, plus tri-specific immuno-oncology candidates KJ-101 and KJ-102. The company commercializes its pipeline and platform primarily through clinical development partnerships and licensing arrangements with pharmaceutical companies and research organizations.

Product overview

KisoJi Biotechnology offers an integrated antibody discovery platform comprising three core technology components: KisoMouse™ (transgenic mouse platform for generating diverse single domain antibodies), KisoSeek™ (AI-enabled antibody paratope fingerprinting and mapping technology), and KisoBody™ (modular multi-specific antibody format). The platform enables visualization of complete immune responses to identify antibody clusters with desired properties and optimize lead candidate selection. From this platform, the company has developed a preclinical pipeline including KJ-103 (a naked anti-TROP2 antibody for solid tumors in IND-enabling studies), KJ-101 (tri-specific antibody for solid tumors in IND-enabling), and KJ-102 (tri-specific antibody for acute myeloid leukemia in research).

Differentiator

Problem solved

Functional benefit

Products and services

• KisoMouse Proprietary multi-species transgenic mouse platform that generates the widest array of single domain antibodies of any animal species; provides the foundation for KisoJi's antibody discovery pipeline and platform partnerships.
• KisoSeek (AI-KisoSeek)

Quantifiable outcome

• KJ-103 has demonstrated significant anti-tumor potency with no evidence of toxicity or resistance across multiple preclinical solid tumor models.
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Evolution Venture PartnersminorStrategic or Co-development Partner · 2 December 2024Exclusive strategic advisor to KisoJi in connection with the $41 million financing.
• Cancer Research UKcoreStrategic or Co-development Partner · 24 October 2024Landmark agreement for first-in-human clinical trial of KJ-103, a naked anti-TROP2 antibody, in selected TROP2 expressing solid tumours. Cancer Research UK's Centre for Drug Development (CDD) will sponsor, design and deliver a Phase 1/2a clinical trial of approximately 100 patients. KisoJi will supply the antibody for the clinical trial and work with CDD to complete the preclinical package. Cancer Research Horizons will manage the commercial relationship.
• LifeArcminorImplementation/ SI/ Consulting PartnerKJ-103 was humanised by LifeArc, a UK-based medical research charity focused on translating discoveries into new treatments and diagnostics.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AbCellera Biologics: AI-powered antibody discovery platform partnering with pharma to generate therapeutic antibodies; comparable to KisoJi's KisoMouse + KisoSeek stack in technology and partnership-driven business model.
• Adimab: Leading antibody discovery platform using proprietary yeast and phage display plus AI to identify lead candidates for pharma partners; directly analogous to KisoJi's antibody discovery + partnership model.
• Zymeworks: Clinical-stage biotech developing multi-specific antibody therapeutics (Azymetric platform) with pharma partnerships; directly comparable to KisoJi's KisoBody multi-specific format and pipeline.
• Compass Therapeutics: Clinical-stage biotech developing multi-specific antibodies for oncology with a discovery platform and pipeline of multi-specific candidates; comparable in modality and stage.
• Inhibrx Biosciences: Clinical-stage biotech developing multi-specific antibody therapeutics using sdAb-based scaffolds; closely comparable to KisoJi's single-domain antibody and multi-specific platform.
• MacroGenics: Clinical-stage biotech developing multi-specific antibodies (DART and TRIDENT platforms) targeting oncology including TROP2 and immune checkpoints; comparable in modality, target space, and stage.

Broad incumbents

• Harpoon Therapeutics (now Merck): Developed T-cell-engaging multi-specific antibodies (TriTAC platform) acquired by Merck; comparable multi-specific modality and oncology focus as a now-broad-incumbent player.
• Gilead Sciences (Trodelvy): Holds the leading approved TROP2-targeting therapy (Trodelvy/sacituzumab govitecan) and represents the dominant competitive incumbent against KJ-103 in TROP2-expressing tumors.
• Daiichi Sankyo (Datrowza / TROP2 ADC): Co-developing Datopotamab deruxtecan with AstraZeneca, a TROP2-directed ADC; major competing program in KJ-103's target indication space.

Emerging players

• Atreca: Antibody discovery platform leveraging immune response analysis to identify therapeutic antibodies; comparable discovery approach (immune repertoire-based selection) but at an earlier commercial stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kisoji-biotechnology-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KisoJi Biotechnology